ArriVent BioPharma, Inc. (AVBP) company profile
Close on Nov 17, 2026Market cap $527.10MP/E –Yield –
About ArriVent BioPharma
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical company that identifies, develops, and commercializes differentiated cancer therapies, with a primary focus on solid tumors. Its lead product candidate is firmonertinib, an investigational tyrosine kinase inhibitor evaluated in clinical trials for non-small cell lung cancer characterized by epidermal growth factor receptor mutations, notably exon 20 insertions and PACC mutations. In addition, the firm is developing a pipeline of novel therapeutics, including next-generation antibody drug conjugates such as ARR-217 for gastrointestinal cancers and other solid tumors. Its prospective customers and end users are cancer patients with underserved oncological conditions.
The company operates globally through collaborative clinical development programs across regions including the United States, Europe, and Asia. It sources therapeutic candidates worldwide—frequently initiating partnerships in China—and conducts international multi-center clinical trials, with commercial rights spanning territories outside greater China. Its corporate headquarters is not stated in the provided text.
Summary of the business section of ArriVent BioPharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ArriVent BioPharma, Inc.
- Founded
- 2021
- Headquarters
- Newtown Square, PA
- Address
- 18 Campus Blvd., Suite 100 19073-3269
- Phone
- (240) 780-6356
- Website
- arrivent.com
- Employees
- 77, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- AVBP
- Exchange
- Nasdaq
- IPO date
- Jan 26, 2024
- Shares outstanding
- 49M, Aug 10, 2026
- Public float
- $762.66M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1868279
- CUSIP
- 04272N102
- ISIN
- US04272N1028
- FIGI
- BBG011N37VQ0
- Share class FIGI
- BBG011N37VW3
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stuart Lutzker | President of R&D, Director | 147,744 |
| Zhengbin Yao | President and CEO, Director | 613,138 |
| Robin LaChapelle | Chief Operating Officer | 570,906 |
| Winston Kung | Chief Financial Officer | – |
| James Paul Kastenmayer | General Counsel | 7,386 |
| John Hohneker | Director | – |
| Chris Nolet | Director | – |
| Kristine Peterson | Director | – |
| Merdad Parsey | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Zhengbin (Bing) Yao, Ph.D Chief Executive Officer and President | $596.67K | $8.41M | $358.00K | $14.00K | $9.37M | +290% |
| Stuart Lutzker, M.D., Ph.D President, Research and Development | $515.78K | $2.65M | $247.57K | $14.00K | $3.43M | +248% |
| Winston Kung, MBA Chief Financial Officer and Treasurer | $492.42K | $2.65M | $246.29K | $14.00K | $3.41M | +86% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 26, 2024
- Offer price
- $18.00
- Securities offered
- 9,722,222
- Gross proceeds
- $175.00M
- Exchange
- Nasdaq
- First trading day
- Jan 26, 2024
- First-day close
- $20.00+11.1%
- Lock-up ends (est.)
- Jul 24, 2024
“The initial public offering price is $18.00 per share of common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 77 employees, all of whom were full-time and 45 of whom were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 13, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 26, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 23, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?